Project Grant R01HL172809
Award Date
1/6/25
Completion Date
11/30/29
Dollars Obligated
$560K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38163, USA
Similar Awards
This federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837). The $2,009,636 award to The Leland Stanford Junior University will fund research to investigate the regulatory mechanisms governing smooth muscle cell phenotype transitions and their relationship to vascular disease risk. Key research objectives include mapping the epigenomic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will provide $381,250 to Clemson University to conduct research on identifying novel atheroprotective mechanisms related to vascular smooth muscle cell cholesterol efflux. The research aims to rigorously analyze the potential atheroprotective impacts of increased expression of the ABC transporters ABCA1 and ABCG1 in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $874,792 to Vanderbilt University Medical Center from July 2024 to June 2028. The project aims to address residual atherosclerotic cardiovascular disease (ASCVD) risk among patients who continue to experience myocardial infarctions or strokes despite treatment to lower LDL-cholesterol and blood pressure. The key objectives are to: (1)...
This federal Project Grant award, totaling $719,050.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research led by Louisiana State University Health Sciences Center-Shreveport (LSU Health Sciences Center-Shreveport) to investigate the role of the EPHA2 receptor in regulating atherosclerotic smooth muscle cell phenotype and plaque stability. The key focus is to characterize how EPHA2...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,892 to Asclepia Technology LLC to conduct a proof-of-concept study on developing a targeted cellular therapy for treating atherosclerotic vascular disease in minority patients. The project aims to manufacture and test several prototypes of dual-functional, echogenic immunoliposomes...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $784,046 to the Rector & Visitors of the University of Virginia (UVA) to conduct research modeling cell-specific signaling pathways involving the LRP1 receptor in the context of acute myocardial infarction (AMI) and heart failure. The award aims to 1) expand and validate a signaling network that predicts how early...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $705,405 to The Leland Stanford Junior University to conduct research on adventitial fibroblasts and their role in atherosclerosis. The research aims to identify novel cell-based mechanisms and genetic factors influencing atherosclerotic plaque formation and calcification. Key objectives include determining how genetic ablation of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $700,398 to The Trustees of Columbia University in the City of New York to conduct research on integrating spatial transcriptomics, genetics, and histomorphology for causal inference in atherosclerotic cardiovascular disease. The key objectives are to: 1) apply machine learning algorithms to analyze histology images from...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), totaling $528,179 and awarded on March 4, 2025, supports research to investigate the systemic effects of ischemia-induced reprogramming of monocytes to improve neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key research goals are to: 1) determine if extracellular vesicles mediate the systemic...
This federal Project Grant award, totaling $2,218,392.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The primary objective is to investigate the role of the lymphatic system and its coupling with the glymphatic system in the pathogenesis of cerebral small vessel disease (CSVD) in the context of chronic hypertension. Key activities include: Characterizing lymphatic drainage and glymphatic transport...